PROPEL Mini is clinically proven to improve outcomes of frontal sinus surgery2
PRIMARY ENDPOINT: PROPEL Mini delivers significant reduction in the need for postoperative interventions2
PROPEL Mini reduced the need for postoperative interventions vs surgery alone, at 30 days following frontal sinus surgery (38.8% vs 62.7%; N=80)*†
SECONDARY ENDPOINTS: PROPEL Mini delivers added benefits to patients3
The benefits of PROPEL Mini in reducing the need for postoperative interventions vs surgery alone following frontal sinus surgery were supported by reductions in occlusion/restenosis, oral steroids, and surgical intervention3
RELATIVE REDUCTIONS AT DAY 303
Benefits were also observed in inflammation and size of the frontal sinus opening, with PROPEL Mini vs surgery alone at Day 30, as per clinical investigators3
For significant improvements to patient outcomes following sinus surgery, add PROPEL Mini to your battle for the frontal sinus
PATIENT A*
Surgery
alone
Day 0
Day 30
surgery+
PROPEL Mini
Day 0
Day 30
Optimal treatment following frontal sinus surgery with a full arsenal of options including PROPEL Mini and PROPEL Contour, can help improve patient outcomes
PROPEL Mini has a PROVEN safety profile2
The safety profile of PROPEL Mini was established in the PROGRESS study (Mini Cohort), which included 80 patients.2 The most common adverse reactions observed in ≥2% of subjects were acute sinusitis, chronic sinusitis, headache, upper respiratory tract infection, epistaxis, presyncope, acute otitis media, asthma, nasal congestion, eyelid edema, influenza, nasal polyps, nasopharyngitis, and nausea.